These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Examination and evaluation of sIL-6R, sgp130 in serum in patients with chronic hepatopathy].
    Author: Shang J, Xu Y, Zhang H.
    Journal: Zhonghua Gan Zang Bing Za Zhi; 2000 Apr; 8(2):87-8. PubMed ID: 10861111.
    Abstract:
    OBJECTIVE: To observe the variation of soluble interleukin-6 receptor (sIL-6R) and soluble interleukin-6 receptor beta strands (sgp130) in patients with chronic hepatopath. METHODS: We examined sIL-6R and sgp130 level in 40 patients with chronic hepatitis (CH), 15 with cirrhosis following hepatitis, and 35 normal controls (NC) in serum by enzyme linked immunosorbent assay (ELISA) method. RESULTS: The content of sIL-6R and sgp130 in serum was higher in CH group (224.27 mug/L and 489.35 mug/L, respectively) than NC group (174.81 mug/L and 273.64 mug/L respectively). The two parameters above in patients with hepatocirrhosis were higher than those in patients with chronic hepatitis, and the content in order of quantity was severe>moderate>slight. There was significant difference among the three groups (P<0.05, P<0.01), and positive correlation between sIL-6R and sgp130 level (r=0.481, P<0.05), between sIL-6R, sgp130 level and total bilirubin level (r=0.417, r=0. 428, P<0.01). While sIL-6R, sgp130 was no significant correlation to ALT (r=0.173, r=0.182, P>0.05). CONCLUSION: sIL-6R and sgp130 in serum are associated with the development of chronic hepatopath, and therefore can guide the assessment of prognosis.
    [Abstract] [Full Text] [Related] [New Search]